Criteria to Report Adverse Drug Withdrawal Events in Clinical Trials: A Systematic Review
Journal of the American Geriatrics Society · 2025-06 · 73 (6) · 1918-1928
DOI: 10.1111/jgs.19457 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of the American Geriatrics Society, online erschienen am 28.03.2025. Verfasst von Jimin J Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montréal, Quebec, Canada. Hauptthemen laut MEDLINE: Deprescriptions, Drug-Related Side Effects and Adverse Reactions, Clinical Trials as Topic, Safety-Based Drug Withdrawals. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fonds de Recherche du Québec-Santé, Health Canada, Fonds de Recherche du Québec - Santé.
Abstract (Originalsprache)
Background
Polypharmacy is a major risk factor for adverse drug events (ADEs), which are a common cause of hospitalization, especially among older adults. Deprescribing is a promising strategy to prevent ADEs; however, clinicians may hesitate to deprescribe for fear of causing adverse drug withdrawal events (ADWEs). Collectively, ADWEs are the re‐emergence of symptoms or a disease state due to the discontinuation of a medication. Although capturing ADWEs is critical to understanding the complications that might arise from deprescribing, these events may not be routinely or systematically captured in clinical trials.
Objectives
We aimed to determine the frequency of ADWE reporting, compare the strengths and limitations of different approaches, and compare the rates of the number of ADWEs detected across trials.
Methods
A systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses checklist. The search strategy was developed with a research librarian, and studies were identified using Ovid Medline, Embase, and the Cochrane Central Register of Controlled Trials from inception to July 2, 2024. We included all randomized controlled trials testing a deprescribing intervention in older adults (mean or median age ≥ 65 years) and analyzed a subsample of the studies reporting ADWEs as an outcome.
Results
Among the 139 eligible studies that were identified, only 12 reported an ADWE. These studies utilized 6 approaches to capture ADWEs: Naranjo ADWE Probability Scale; clinical monitoring for specific withdrawal symptoms; identification through ICD‐10 codes; identification of ADWEs as a subset of confirmed ADEs; patient/caregiver self‐report; and clinical judgment.
Conclusion
Results confirmed that few deprescribing studies capture ADWEs and there is a lack of standardized reporting. A harmonized approach to capturing ADWEs with specific criteria could ensure more consistent results in deprescribing trials, improve our understanding of this important outcome, and facilitate future meta‐analyses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montréal, Quebec, Canada.
- Department of Psychiatry, Lady Davis Institute/Jewish General Hospital, McGill University, Montréal, Québec, Canada.
- Division of Geriatrics, Department of Medicine, McGill University Health Centre, Montréal, Québec, Canada.
- Department of Epidemiology and Biostatistics, McGill University Health Centre, Montréal, Québec, Canada.
- Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montréal, Québec, Canada.
- Division of General Internal Medicine, Department of Medicine, McGill University Health Centre, Montréal, Québec, Canada.
ORCID-Profile: Émilie Bortolussi-Courval, Todd C Lee, Emily G McDonald
Förderung
- Fonds de Recherche du Québec-Santé
- Health Canada
- Fonds de Recherche du Québec - Santé
Zitieren
APA
Lee, J. J., Bortolussi-Courval, É., Filosa, E., Rej, S., Godard-Sebillote, C., Tamblyn, R., Lee, T. C., & McDonald, E. G. (2025). Criteria to Report Adverse Drug Withdrawal Events in Clinical Trials: A Systematic Review. Journal of the American Geriatrics Society, 73(6), 1918-1928. https://doi.org/10.1111/jgs.19457
Vancouver
Lee JJ, Bortolussi-Courval É, Filosa E, Rej S, Godard-Sebillote C, Tamblyn R, et al. Criteria to Report Adverse Drug Withdrawal Events in Clinical Trials: A Systematic Review. Journal of the American Geriatrics Society. 2025;73(6):1918-1928. doi:10.1111/jgs.19457
BibTeX
@article{Lee2025,
author = {Lee, Jimin J and Bortolussi-Courval, Émilie and Filosa, Eva and Rej, Soham and Godard-Sebillote, Claire and Tamblyn, Robyn and Lee, Todd C and McDonald, Emily G},
title = {Criteria to Report Adverse Drug Withdrawal Events in Clinical Trials: A Systematic Review},
journal = {Journal of the American Geriatrics Society},
year = {2025},
volume = {73},
number = {6},
pages = {1918--1928},
doi = {10.1111/jgs.19457}
}
EUVIMED